NMDA RECEPTOR AS THERAPEUTIC TARGET FOR PARKINSON?S DISEASE

NMDA 受体作为帕金森病的治疗靶点

• 批准号: 8172433
• 负责人: Stella M Papa
• 金额: $ 4.39万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172433
• 关键词: Animal Model; Animals; Antiparkinson Agents; Basal Ganglia; Behavior; Cell Nucleus; Computer Retrieval of Information on Scientific Projects Database; Data; Dopamine; Dose; Drug Kinetics; Funding; Goals; Grant; Immunohistochemistry; Institution; Lesion; Motor; N-Methyl-D-Aspartate Receptors; Neurons; Parkinson Disease; Rattus; Research; Research Personnel; Resources; Source; Structure; Structure of subthalamic nucleus; Testing; United States National Institutes of Health; Work; in vivo; protein distribution; receptor; research study; therapeutic target

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of the studies in this project is to obtain in vivo confirmation of the potential antiparkinsonian effects of blockade of NR2D-type NMDA receptors in an animal model of Parkinson's disease, the 6-OH-dopamine-lesioned rat. These agents are most likely to work by blocking NR2D receptors in the subthalamic nucleus, a structure which is overactive in Parkinson's disease. NR2D receptor blockade may act to normalize the activity in this nucleus. To test this hypothesis, three experiments are planned: (1) We will establish the concentration-effect curve for inhibition of native NR2D-containing NMDA receptors in subthalamic neurons by our best NR2D-selective antagonist. The combination of these data with in vivo pharmacokinetic data will allow us to estimate receptor occupancy as a function of administered dose. (2) We will determine the NR2D protein distribution using immunohistochemistry in normal rats and rats treated with 6-OH-dopamine to confirm that NR2D receptors are present in this animal model of Parkinson's disease. (3) We will evaluate the ability of selective blockade of NR2D-containing receptors in basal ganglia neurons to alter motor behavior in 6-OHDA-lesioned animals.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 该项目研究的目的是在帕金森病动物模型（6-OH-多巴胺损伤的大鼠）中体内证实阻断 NR2D 型 NMDA 受体的潜在抗帕金森病作用。 这些药物最有可能通过阻断丘脑底核中的 NR2D 受体发挥作用，丘脑底核是一种在帕金森病中过度活跃的结构。 NR2D 受体阻断可能会使该细胞核的活性正常化。 为了检验这一假设，计划进行三个实验：（1）我们将建立我们最好的 NR2D 选择性拮抗剂抑制底丘脑神经元中含有天然 NR2D 的 NMDA 受体的浓度效应曲线。 这些数据与体内药代动力学数据的结合将使我们能够估计受体占用率作为给药剂量的函数。 (2)我们将使用免疫组织化学测定正常大鼠和用6-OH-多巴胺处理的大鼠中NR2D蛋白的分布，以确认NR2D受体存在于该帕金森病动物模型中。 (3) 我们将评估选择性阻断基底神经节神经元中含有 NR2D 的受体改变 6-OHDA 损伤动物运动行为的能力。